Mark Copley is Chief Executive Officer at Copley Scientific. For eight years he was Technical Sales Manager and product specialist for the company’s range of inhaler testing equipment, before becoming the Sales Director in 2009.

Mr Copley is considered a leading authority in testing methods and systems for MDIs, DPIs, nebulisers and nasal sprays; authoring and contributing to more than 50 published articles. He also provides application support and consultancy and runs focused training workshops for the inhaled drug testing sector of the pharmaceutical industry. An invited member of the European Pharmaceutical Aerosol Group (EPAG) impactor sub-team, he has also made recommendations to the Inhalanda working group, leading to subsequent revisions to EP and USP monographs. As part of Copley Scientific’s associate membership of IPAC-RS, Mr Copley participates in a number of working groups with a view to enhancing the regulatory science of orally inhaled and nasal drug products (OINDPs).

Mr Copley graduated from the University of Bath, UK, in 2000 with a Masters’ Degree in Aerospace Engineering.

More contributions